Loading
Life sciences · Review
Climacteric · October 9, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Review.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Menopause represents a critical transition that affects multiple organ systems, including the lungs. Declining levels of estrogen, progesterone and androgens alter airway function, inflammatory balance and tissue structure, contributing to changes in pulmonary physiology. Although these mechanisms provide a biological basis for potential associations with asthma, chronic obstructive pulmonary disease and lung cancer, the existing evidence remains inconclusive. Similarly, the effects of menopausal hormone therapy (MHT) on pulmonary outcomes are not clearly defined. This narrative review summarizes the physiological effects of sex hormones on lung function, describes menopause-related structural and inflammatory changes, and discusses the implications of MHT and androgen therapy for respiratory health in women.